The Safety and Efficacy of Induction Chemoimmunotherapy Followed by Radiotherapy and Consolidation Immunotherapy in Locally Advanced NSCLC
Journal of Thoracic Oncology(2023)
Abstract
Although PACIFIC trial has greatly changed treatment modality of locally advanced non-small-cell lung cancer (NSCLC), up to 50% patients are not candidates for concurrent chemoradiation therapy due to poor performance status, or large tumor burden. This study evaluated safety and efficacy of induction chemotherapy plus tislelizumab, a programmed cell death protein 1 (PD-1) inhibitor, followed by thoracic radiotherapy and consolidation tislelizumab in patients with unresectable, stage III NSCLC.
MoreTranslated text
Key words
Induction chemoimmunotherapy,Locally advanced non-small cell lung cancer,efficacy
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined